Eli Lilly is making a significant strategic shift, announcing a series of acquisitions that signal the pharmaceutical giant’s commitment to expanding beyond its blockbuster weight-loss drugs. The company plans to acquire three specialized biotech firms for a combined investment of nearly $4 billion, marking one of its most ambitious moves into the infectious disease space. […] The post Eli Lilly invests $4 billion acquiring 3 vaccine companies appeared first on Rolling Out .
Get in touch with us
Reach out to the Hayti team about
collaborating or working together.



